Liver Cancer最新文献

{"title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8⁺PD-1^int TILs and Results in Tumor Remission in Experimental Liver Cancer.","authors":"Sandra Bufe,&nbsp;Artur Zimmermann,&nbsp;Sarina Ravens,&nbsp;Immo Prinz,&nbsp;Laura Elisa Buitrago-Molina,&nbsp;Robert Geffers,&nbsp;Norman Woller,&nbsp;Florian Kühnel,&nbsp;Steven R Talbot,&nbsp;Fatih Noyan,&nbsp;Michael Peter Manns,&nbsp;Heiner Wedemeyer,&nbsp;Matthias Hardtke-Wolenski,&nbsp;Elmar Jaeckel,&nbsp;Ana C Davalos-Misslitz","doi":"10.1159/000526899","DOIUrl":"https://doi.org/10.1159/000526899","url":null,"abstract":"<p><strong>Background: </strong>Checkpoint inhibitors act on exhausted CD8⁺ T cells and restore their effector function in chronic infections and cancer. The underlying mechanisms of action appear to differ between different types of cancer and are not yet fully understood.</p><p><strong>Methods: </strong>Here, we established a new orthotopic HCC model to study the effects of checkpoint blockade on exhausted CD8⁺ tumor-infiltrating lymphocytes (TILs). The tumors expressed endogenous levels of HA, which allowed the study of tumor-specific T cells.</p><p><strong>Results: </strong>The induced tumors developed an immune-resistant TME in which few T cells were found. The few recovered CD8⁺ TILs were mostly terminally exhausted and expressed high levels of PD-1. PD-1/CTLA-4 blockade resulted in a strong increase in the number of CD8⁺ TILs expressing intermediate amounts of PD-1, also called progenitor-exhausted CD8⁺ TILs, while terminally exhausted CD8⁺ TILs were almost absent in the tumors of treated mice. Although transferred naïve tumor-specific T cells did not expand in the tumors of untreated mice, they expanded strongly after treatment and generated progenitor-exhausted but not terminally exhausted CD8⁺ TILs. Unexpectedly, progenitor-exhausted CD8⁺ TILs mediated the antitumor response after treatment with minimal changes in their transcriptional profile.</p><p><strong>Conclusion: </strong>In our model, few doses of checkpoint inhibitors during the priming of transferred CD8⁺ tumor-specific T cells were sufficient to induce tumor remission. Therefore, PD-1/CTLA-4 blockade has an ameliorative effect on the expansion of recently primed CD8⁺ T cells while preventing their development into terminally exhausted CD8⁺ TILs in the TME. This finding could have important implications for future T-cell therapies.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 2","pages":"129-144"},"PeriodicalIF":13.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/c4/lic-0012-0129.PMC10267567.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9648640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones.","authors":"Jens Mittler,&nbsp;Stefan Heinrich,&nbsp;Martina Koch,&nbsp;Maria Hoppe-Lotichius,&nbsp;Ali Hadian,&nbsp;Arndt Weinmann,&nbsp;Roman Kloeckner,&nbsp;Peter Robert Galle,&nbsp;Hauke Lang","doi":"10.1159/000528830","DOIUrl":"https://doi.org/10.1159/000528830","url":null,"abstract":"<p><strong>Introduction: </strong>The literature on liver transplantation (LT) for cirrhosis-associated hepatocellular carcinoma (cirr-HCC) in elderly patients (≥65 years of age) is scarce. The aim of this study was therefore to analyze the outcome after LT for cirr-HCC in elderly patients in our single-center experience.</p><p><strong>Methods: </strong>All consecutive patients who underwent LT for cirr-HCC at our center were identified from our prospectively collected LT database and stratified into an elderly (≥65 years) and a younger (<65 years) cohort. Perioperative mortality as well as Kaplan-Meier estimations of overall (OS) and recurrence-free survival (RFS) were compared between age strata. A subgroup analysis was performed for patients with HCC only inside Milan criteria. For further oncological comparison, outcome in the subgroup of elderly LT recipients with HCC inside Milan was also compared to a group of elderly patients undergoing liver resection for cirr-HCC inside Milan extracted from our institutional liver resection database.</p><p><strong>Results: </strong>Out of 369 consecutive patients with cirr-HCC who underwent LT between 1998 and 2022 at our center, we identified 97 elderly (with a subgroup of 14 septuagenarians) and 272 younger LT patients. 5- and 10-year OS in elderly compared to younger LT patients was 63% and 52% versus 63% and 46% (<i>p</i> = 0.67), respectively, while 5- and 10-year RFS was 58% and 49% versus 58% and 44% (<i>p</i> = 0.69). 5-/10-year OS and RFS in 50 elderly LT recipients with HCC inside Milan were 68%/55% and 62%/54%, respectively, which compared to 46%/38% (<i>p</i> = 0.07) and 26%/14% (<i>p</i> < 0.0001) in elderly patients after liver resection for cirr-HCC inside Milan.</p><p><strong>Conclusion: </strong>Our results in almost 100 elderly patients after LT for cirr-HCC show that older age per se should not be considered a contraindication to LT and that selected elderly patients older than 65 and even 70 years benefit from LT as much as younger ones.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 2","pages":"171-177"},"PeriodicalIF":13.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deficient Immune Response following SARS-CoV-2 Vaccination in Patients with Hepatobiliary Carcinoma: A Forgotten, Vulnerable Group of Patients.","authors":"Malte B Monin,&nbsp;Leona I Baier,&nbsp;Jens G Gorny,&nbsp;Moritz Berger,&nbsp;Taotao Zhou,&nbsp;Robert Mahn,&nbsp;Farsaneh Sadeghlar,&nbsp;Christian Möhring,&nbsp;Christoph Boesecke,&nbsp;Kathrin van Bremen,&nbsp;Jürgen K Rockstroh,&nbsp;Christian P Strassburg,&nbsp;Anna-Maria Eis-Hübinger,&nbsp;Matthias Schmid,&nbsp;Maria A Gonzalez-Carmona","doi":"10.1159/000529608","DOIUrl":"https://doi.org/10.1159/000529608","url":null,"abstract":"<p><strong>Introduction: </strong>Data on immune response rates following vaccination for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in patients with hepatobiliary carcinoma (HBC) are rare. However, impaired immunogenicity must be expected due to the combination of chronic liver diseases (CLDs) with malignancy and anticancer treatment.</p><p><strong>Methods: </strong>In this prospective, longitudinal study, 101 patients were included, of whom 59 were patients with HBC under anticancer treatment. A cohort of patients with a past medical history of gastrointestinal cancer, of whom 28.6% had HBC without detectable active tumor disease having been off therapy for at least 12 months, served as control. Levels of SARS-CoV-2 anti-spike IgG, surrogate neutralization antibodies (sNABs), and cellular immune responses were compared. In uni- and multivariable subgroup analyses, risk factors for impaired immunogenicity were regarded. Data on rates and clinical courses of SARS-CoV-2 infections were documented.</p><p><strong>Results: </strong>In patients with HBC under active treatment, levels of SARS-CoV-2 anti-spike IgG were significantly lower (2.55 log₁₀ BAU/mL; 95% CI: 2.33-2.76; <i>p</i> < 0.01) than in patients in follow-up care (3.02 log₁₀ BAU/mL; 95% CI: 2.80-3.25) 4 weeks after two vaccinations. Antibody levels decreased over time, and differences between the groups diminished. However, titers of SARS-CoV-2 sNAB were for a longer time significantly lower in patients with HBC under treatment (64.19%; 95% CI: 55.90-72.48; <i>p</i> < 0.01) than in patients in follow-up care (84.13%; 95% CI: 76.95-91.31). Underlying CLD and/or liver cirrhosis Child-Pugh A or B (less than 8 points) did not seem to further impair immunogenicity. Conversely, chemotherapy and additional immunosuppression were found to significantly reduce antibody levels. After a third booster vaccination for SARS-CoV-2, levels of total and neutralization antibodies were equalized between the groups. Moreover, cellular response rates were balanced. Clinically, infection rates with SARS-CoV-2 were low, and no severe courses were observed.</p><p><strong>Conclusion: </strong>Patients with active HBC showed significantly impaired immune response rates to basic vaccinations for SARS-CoV-2, especially under chemotherapy, independent of underlying cirrhotic or non-cirrhotic CLD. Although booster vaccinations balanced differences, waning immunity was observed over time and should be monitored for further recommendations. Our data help clinicians decide on individual additional booster vaccinations and/or passive immunization or antiviral treatment in patients with HBC getting infected with SARS-CoV-2.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 4","pages":"339-355"},"PeriodicalIF":13.8,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).","authors":"Jian Zhou,&nbsp;Huichuan Sun,&nbsp;Zheng Wang,&nbsp;Wenming Cong,&nbsp;Mengsu Zeng,&nbsp;Weiping Zhou,&nbsp;Ping Bie,&nbsp;Lianxin Liu,&nbsp;Tianfu Wen,&nbsp;Ming Kuang,&nbsp;Guohong Han,&nbsp;Zhiping Yan,&nbsp;Maoqiang Wang,&nbsp;Ruibao Liu,&nbsp;Ligong Lu,&nbsp;Zhenggang Ren,&nbsp;Zhaochong Zeng,&nbsp;Ping Liang,&nbsp;Changhong Liang,&nbsp;Min Chen,&nbsp;Fuhua Yan,&nbsp;Wenping Wang,&nbsp;Jinlin Hou,&nbsp;Yuan Ji,&nbsp;Jingping Yun,&nbsp;Xueli Bai,&nbsp;Dingfang Cai,&nbsp;Weixia Chen,&nbsp;Yongjun Chen,&nbsp;Wenwu Cheng,&nbsp;Shuqun Cheng,&nbsp;Chaoliu Dai,&nbsp;Wengzhi Guo,&nbsp;Yabing Guo,&nbsp;Baojin Hua,&nbsp;Xiaowu Huang,&nbsp;Weidong Jia,&nbsp;Qiu Li,&nbsp;Tao Li,&nbsp;Xun Li,&nbsp;Yaming Li,&nbsp;Yexiong Li,&nbsp;Jun Liang,&nbsp;Changquan Ling,&nbsp;Tianshu Liu,&nbsp;Xiufeng Liu,&nbsp;Shichun Lu,&nbsp;Guoyue Lv,&nbsp;Yilei Mao,&nbsp;Zhiqiang Meng,&nbsp;Tao Peng,&nbsp;Weixin Ren,&nbsp;Hongcheng Shi,&nbsp;Guoming Shi,&nbsp;Ming Shi,&nbsp;Tianqiang Song,&nbsp;Kaishan Tao,&nbsp;Jianhua Wang,&nbsp;Kui Wang,&nbsp;Lu Wang,&nbsp;Wentao Wang,&nbsp;Xiaoying Wang,&nbsp;Zhiming Wang,&nbsp;Bangde Xiang,&nbsp;Baocai Xing,&nbsp;Jianming Xu,&nbsp;Jiamei Yang,&nbsp;Jianyong Yang,&nbsp;Yefa Yang,&nbsp;Yunke Yang,&nbsp;Shenglong Ye,&nbsp;Zhenyu Yin,&nbsp;Yong Zeng,&nbsp;Bixiang Zhang,&nbsp;Boheng Zhang,&nbsp;Leida Zhang,&nbsp;Shuijun Zhang,&nbsp;Ti Zhang,&nbsp;Yanqiao Zhang,&nbsp;Ming Zhao,&nbsp;Yongfu Zhao,&nbsp;Honggang Zheng,&nbsp;Ledu Zhou,&nbsp;Jiye Zhu,&nbsp;Kangshun Zhu,&nbsp;Rong Liu,&nbsp;Yinghong Shi,&nbsp;Yongsheng Xiao,&nbsp;Lan Zhang,&nbsp;Chun Yang,&nbsp;Zhifeng Wu,&nbsp;Zhi Dai,&nbsp;Minshan Chen,&nbsp;Jianqiang Cai,&nbsp;Weilin Wang,&nbsp;Xiujun Cai,&nbsp;Qiang Li,&nbsp;Feng Shen,&nbsp;Shukui Qin,&nbsp;Gaojun Teng,&nbsp;Jiahong Dong,&nbsp;Jia Fan","doi":"10.1159/000530495","DOIUrl":"https://doi.org/10.1159/000530495","url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.</p><p><strong>Summary: </strong>Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer.</p><p><strong>Key messages: </strong>The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the \"Health China 2030 Blueprint.\"</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 5","pages":"405-444"},"PeriodicalIF":13.8,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.","authors":"Darren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, Cheng Han Ng, Benjamin Nah, Clarissa Fu, Jieling Xiao, Benjamin Koh, Phoebe Wen Lin Tay, Eunice X Tan, Margaret Teng, Nicholas Syn, Mark D Muthiah, Nobuharu Tamaki, Sung Won Lee, Beom Kyung Kim, Thomas Yau, Arndt Vogel, Rohit Loomba, Daniel Q Huang","doi":"10.1159/000529824","DOIUrl":"10.1159/000529824","url":null,"abstract":"<p><strong>Background: </strong>Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC.</p><p><strong>Summary: </strong>In this systematic review and individual patient data meta-analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from inception till September 2022 for RCTs that provided data for overall survival (OS) and progression-free survival (PFS) for sorafenib monotherapy as first-line systemic therapy for advanced HCC. We performed a pooled analysis using reconstructed individual participant data from published Kaplan-Meier curves to obtain robust estimates for OS and PFS. Of 1,599 articles identified, 29 studies (5,525 patients) met the inclusion criteria. Overall, the median OS was 10.4 (95% CI: 9.6-11.4) months. Median OS increased over time, from 9.8 (95% CI: 8.8-10.7) months in studies before 2015 to 13.4 (95% CI: 11.03-15.24) months in studies from 2015 onwards (<i>p</i> < 0.001). OS did not differ by trial phase, geographical region, or study design. The overall median PFS was 4.4 (95% CI: 3.9-4.8) months, but PFS did not improve over time. Sensitivity analysis of studies from 2015 and onwards to account for the introduction of direct-acting antivirals determined that hepatitis C virus was associated with reduced mortality (<i>p</i> < 0.001). There was minimal heterogeneity in the estimates for OS (all <i>I</i>² ≤ 33).</p><p><strong>Key messages: </strong>Survival outcomes for sorafenib in advanced HCC have improved over time. These data have important implications for clinical trial design.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 5","pages":"445-456"},"PeriodicalIF":11.6,"publicationDate":"2023-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma.","authors":"Yoshikuni Kawaguchi,&nbsp;Ryosuke Tateishi,&nbsp;Norihiro Kokudo,&nbsp;Kiyoshi Hasegawa","doi":"10.1159/000530300","DOIUrl":"https://doi.org/10.1159/000530300","url":null,"abstract":"Not applicable","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 5","pages":"494-496"},"PeriodicalIF":13.8,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.","authors":"Brian De, Rituraj Upadhyay, Kaiping Liao, Tiffany Kumala, Christopher Shi, Grace Dodoo, Joseph Abi Jaoude, Kelsey L Corrigan, Gohar S Manzar, Kathryn E Marqueen, Vincent Bernard, Sunyoung S Lee, Kanwal P S Raghav, Jean-Nicolas Vauthey, Ching-Wei D Tzeng, Hop S Tran Cao, Grace Lee, Jennifer Y Wo, Theodore S Hong, Christopher H Crane, Bruce D Minsky, Grace L Smith, Emma B Holliday, Cullen M Taniguchi, Albert C Koong, Prajnan Das, Milind Javle, Ethan B Ludmir, Eugene J Koay","doi":"10.1159/000530134","DOIUrl":"10.1159/000530134","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT.</p><p><strong>Methods: </strong>We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5-97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling.</p><p><strong>Results: </strong>We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8-11) and 21 months (CI: 17-26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; <i>p</i> = 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; <i>p</i> = 0.005) and receipt of L-RT (HR: 0.40; <i>p</i> = 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 3","pages":"198-208"},"PeriodicalIF":11.6,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/2f/lic-2023-0012-0003-530134.PMC10427952.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10233339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.","authors":"Masatoshi Kudo","doi":"10.1159/000530079","DOIUrl":"10.1159/000530079","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 2","pages":"95-102"},"PeriodicalIF":11.6,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/ad/lic-0012-0095.PMC10267513.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.","authors":"Masatoshi Kudo,&nbsp;Richard S Finn,&nbsp;Ann-Lii Cheng,&nbsp;Andrew X Zhu,&nbsp;Michel Ducreux,&nbsp;Peter R Galle,&nbsp;Naoya Sakamoto,&nbsp;Naoya Kato,&nbsp;Michitaka Nakano,&nbsp;Jing Jia,&nbsp;Arndt Vogel","doi":"10.1159/000529996","DOIUrl":"https://doi.org/10.1159/000529996","url":null,"abstract":"<p><strong>Introduction: </strong>Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score.</p><p><strong>Methods: </strong>Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion, and Child-Pugh class A liver function were randomized 2:1 to receive atezolizumab 1,200 mg + bevacizumab 15 mg/kg every 3 weeks or sorafenib 400 mg twice daily. Overall survival (OS) and progression-free survival (PFS) were assessed in the intention-to-treat population by ALBI/modified (m)ALBI grade. Time to deterioration (TTD; defined as time to 0.5-point increase from the baseline ALBI score over 2 visits or death) of liver function and safety were investigated.</p><p><strong>Results: </strong>Of 501 enrolled patients, 336 were randomized to receive atezolizumab + bevacizumab (ALBI grade [G] 1: <i>n</i> = 191; G2: <i>n</i> = 144 [mALBI G2a: <i>n</i> = 72, G2b: <i>n</i> = 72]; missing ALBI grade: <i>n</i> = 1) and 165 to sorafenib (ALBI G1: <i>n</i> = 87; G2: <i>n</i> = 78 [mALBI G2a: <i>n</i> = 37; G2b: <i>n</i> = 41]). Median follow-up was 15.6 months. OS and PFS improved with atezolizumab + bevacizumab versus sorafenib in patients with ALBI G1 (OS HR: 0.50 [95% CI: 0.35, 0.72]; PFS HR: 0.61 [95% CI: 0.45, 0.82]). In patients with ALBI G2 or mALBI G2a or G2b, PFS was numerically longer with atezolizumab + bevacizumab versus sorafenib, but no OS benefit was seen. Median TTD in the intention-to-treat population was 10.2 months (95% CI: 8.0, 11.0) with atezolizumab + bevacizumab versus 8.6 months (95% CI: 6.2, 11.8) with sorafenib (HR: 0.82 [95% CI: 0.65, 1.03]). Safety profiles of atezolizumab and bevacizumab were consistent with previous analyses, regardless of ALBI grade.</p><p><strong>Conclusion: </strong>ALBI grade appeared to be prognostic for outcomes with both atezolizumab + bevacizumab and sorafenib treatment in patients with HCC. Atezolizumab + bevacizumab preserved liver function for a numerically longer duration than sorafenib.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 5","pages":"479-493"},"PeriodicalIF":13.8,"publicationDate":"2023-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APPLE News","authors":"","doi":"10.1159/000529383","DOIUrl":"https://doi.org/10.1159/000529383","url":null,"abstract":"<br />Liver Cancer 2023;12:93–93","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"7 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138526674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}